Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 860 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Long-term Follow-Up Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine

NCT00359619
View directory record Official record
Conditions
Infections, Papillomavirus, Papillomavirus Vaccines
Interventions
CervarixTM, HPV investigational vaccine GSK568893A, different formulations
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 25 Years · Female only
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Denver, Colorado • Golden, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Oct 21, 2026, 11:02 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

NCT02661464
View directory record Official record
Conditions
Hemorrhagic Fever, Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
0 Years to 71 Years
Enrollment
677 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 21, 2026, 11:02 AM EDT
Terminated No phase listed Observational

Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)

NCT02121899
View directory record Official record
Conditions
Lung Cancer, NSCLC, NSCLC Adenocarcinoma
Interventions
Not listed
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 21, 2026, 11:02 AM EDT
Completed Not applicable Interventional

Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors

NCT02200133
View directory record Official record
Conditions
Adult Hematopoietic Cell Transplant (HCT) Survivors 1-2 Yrs Post Most Recent HCT
Interventions
Individualized Survivorship Care Plan (SCP)
Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Scottsdale, Arizona • Gainesville, Florida • Maywood, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 21, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

NCT02500316
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
MOD-4023
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
3 Years to 11 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 21, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

NCT03639987
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 21, 2026, 11:02 AM EDT
Not yet recruiting Phase 3 Interventional

A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

NCT07733947
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514 Injection, 0.9 % sodium chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 11:02 AM EDT
Enrolling by invitation No phase listed Observational

Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy

NCT04628585
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Safety and efficacy assessments
Other
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
2 Years to 53 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
15
States / cities
Birmingham, Alabama • Oakland, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 21, 2026, 11:02 AM EDT
Completed No phase listed Observational

A Long-term Safety Study of Infliximab (Remicade)

NCT00261976
View directory record Official record
Conditions
Arthritis, Rheumatoid, Crohn Disease, Psoriasis
Interventions
Infliximab (Remicade)
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
Not listed
Enrollment
2,971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 21, 2026, 11:02 AM EDT
Enrolling by invitation No phase listed Observational

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

NCT06363760
View directory record Official record
Conditions
Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
Interventions
Safety and efficacy assessments
Other
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
16
States / cities
Oakland, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 21, 2026, 11:02 AM EDT
Completed No phase listed Observational

Long-Term Safety and Effectiveness of MDMA-Assisted Therapy for PTSD

NCT05066282
View directory record Official record
Conditions
PTSD
Interventions
Not listed
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 21, 2026, 11:02 AM EDT
Completed No phase listed Observational Results available

DEFENDO Long Term Follow-up Study in Stage 1 NK Patients

NCT05552261
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Cenegemin in the DEFENDO Study
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
San Diego, California • Edgewood, Kentucky • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 21, 2026, 11:02 AM EDT
Active, not recruiting No phase listed Observational

Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

NCT05145062
View directory record Official record
Conditions
Blood and Lymphatic Diseases
Interventions
BIVV003, ST-400
Drug
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2038
U.S. locations
7
States / cities
Oakland, California • Sacramento, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 21, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Redirected Auto T Cells for Advanced Myeloma

NCT01352286
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Autologous Genetically modified T cells
Genetic
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 21, 2026, 11:02 AM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension Study of Brazikumab in Crohn's Disease

NCT03961815
View directory record Official record
Conditions
Crohn's Disease, IBD
Interventions
Brazikumab Induction Dose, Brazikumab Maintenance Dose
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Lincoln, California • Clearwater, Florida • Kissimmee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 21, 2026, 11:02 AM EDT
Recruiting Not applicable Interventional

Zimmer Biomet Shoulder Arthroplasty PMCF

NCT04984291
View directory record Official record
Conditions
Shoulder Fractures, Shoulder Arthritis, Shoulder Osteoarthritis, Shoulder Deformity, Shoulder Injuries, Shoulder Pain
Interventions
Alliance Glenoid, Identity Stem
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
20 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
12
States / cities
Irvine, California • Golden, Colorado • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 21, 2026, 11:02 AM EDT
Terminated Phase 2 Interventional Results available

Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048

NCT00157248
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
12
States / cities
La Mesa, California • Pensacola, Florida • Port Charlotte, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 21, 2026, 11:02 AM EDT
Completed Not applicable Interventional

A Long-Term Monitoring Study of the IMT-002 Patients

NCT00976235
View directory record Official record
Conditions
Macular Degeneration
Interventions
IMT - Implantable Miniature Telescope
Device
Lead sponsor
VisionCare, Inc.
Industry
Eligibility
55 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
28
States / cities
Tucson, Arizona • Irvine, California • Los Altos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 21, 2026, 11:02 AM EDT
Enrolling by invitation No phase listed Observational

Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

NCT07660640
View directory record Official record
Conditions
Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Interventions
observational study, VOY-101
Other · Biological
Lead sponsor
Perceive Biotherapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 11:02 AM EDT
Terminated No phase listed Observational

Long-Term Follow-up of Ohio State University Medical Center (OSUMC) Bariatric Patients

NCT00700843
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 21, 2026, 11:02 AM EDT
Terminated No phase listed Observational

A Long-term Follow-up Study of Patients Who Received VOR33

NCT05309733
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
VOR33
Genetic
Lead sponsor
Vor Biopharma
Industry
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
La Jolla, California • Miami, Florida • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 21, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01172938
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 21, 2026, 11:02 AM EDT
Recruiting Phase 2 Interventional

Safe Treatment for Emergency Presentation for Suicidal Ideation and Behavior in Youth

NCT05304065
View directory record Official record
Conditions
Suicide, Suicidal, Self-Harm
Interventions
SAFETY-A within usual ED Care, Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 24 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Sylmar, California • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 21, 2026, 11:02 AM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Standard of Care
Biological · Other
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 11:02 AM EDT